Insight Molecular Diagnostics Inc - IMDX Total Company Value-to-Revenue Ratio

Official company branding of Insight Molecular Diagnostics (IMDX)

The EV/Sales ratio reflects the market valuation of Insight Molecular Diagnostics (IMDX), where the metric stands at 23040.61. This trend is driven by the implementation of energy-efficient systems and eco-friendly packaging within the test development centers. Stability is maintained through strict chemical waste disposal controls and the cleanliness of production lines. Growth is fueled by the automation of the US laboratory complex, which features redundant servers and autonomous power supplies.

EV/Sales Multiple: Insight Molecular Diagnostics Inc (IMDX) for 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Insight Molecular Diagnostics Inc (IMDX)

- market price and analyst price targets:
Initial company analysis:Insight Molecular Diagnostics
Manufactured products of imdxinc.com

This indicator determines the market value of the business relative to its revenue, excluding the impact of debt load to identify the true fundamental valuation trend. By analyzing the EV/Sales trajectory, an investor can compare the capitalization of Insight Molecular Diagnostics (IMDX) with the efficiency of molecular research, where in-house control of genetic processes mitigates reagent outsourcing risks, confirming the asset's resilience.

Competitor analysis

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|prenetics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue